Cargando…

Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial

BACKGROUND AND AIMS: The effect of antidepressant therapy on Inflammatory Bowel Disease (IBD) remains controversial. This trial aimed to assess whether adding venlafaxine to standard therapy for IBD improved the quality of life (QoL), mental health, and disease activity of patients with IBD with anx...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Chang, Chen, Pingrun, Tang, Yu, Zhang, Chuheng, Lei, Na, Luo, Ying, Duan, Shihao, Zhang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160994/
https://www.ncbi.nlm.nih.gov/pubmed/35664492
http://dx.doi.org/10.3389/fpsyt.2022.880058
_version_ 1784719390435966976
author Liang, Chang
Chen, Pingrun
Tang, Yu
Zhang, Chuheng
Lei, Na
Luo, Ying
Duan, Shihao
Zhang, Yan
author_facet Liang, Chang
Chen, Pingrun
Tang, Yu
Zhang, Chuheng
Lei, Na
Luo, Ying
Duan, Shihao
Zhang, Yan
author_sort Liang, Chang
collection PubMed
description BACKGROUND AND AIMS: The effect of antidepressant therapy on Inflammatory Bowel Disease (IBD) remains controversial. This trial aimed to assess whether adding venlafaxine to standard therapy for IBD improved the quality of life (QoL), mental health, and disease activity of patients with IBD with anxious and depressive symptoms. METHODS: A prospective, randomized, double-blind, and placebo-controlled clinical trial was conducted. Participants diagnosed with IBD with symptoms of anxiety or depression were randomly assigned to receive either venlafaxine 150 mg daily or equivalent placebo and followed for 6 months. Inflammatory Bowel Disease Questionnaire (IBDQ), Mayo score, Crohn's disease activity index (CDAI), Hospital Anxiety and Depression Scale (HADS), and blood examination were completed before the enrollment, during, and after the follow-up. Mixed linear models and univariate analyses were used to compare groups. RESULTS: Forty-five patients with IBD were included, of whom 25 were randomized to receive venlafaxine. The mean age was 40.00 (SD = 13.12) years old and 25 (55.6%) were male. Venlafaxine showed a significant improvement on QoL (p < 0.001) and disease course (p = 0.035), a greater reduction in HADS (anxiety: p < 0.001, depression: p < 0.001), Mayo scores (p < 0.001), and CDAI (p = 0.006) after 6 months. Venlafaxine had no effect on IL-10 expression, endoscopic scores, relapse rate, and use rate of biologics and corticosteroids, but did reduce serum level of erythrocyte estimation rate (ESR; p = 0.003), C-reactive protein (CRP; p < 0.001) and tumor necrosis factor-α (TNF-α; p = 0.009). CONCLUSIONS: Venlafaxine has a significantly beneficial effect on QoL, IBD activity, and mental health in patients with IBD with comorbid anxious or depressive symptoms. (Chinese Clinical Trial Registry, ID: ChiCTR1900021496).
format Online
Article
Text
id pubmed-9160994
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91609942022-06-03 Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial Liang, Chang Chen, Pingrun Tang, Yu Zhang, Chuheng Lei, Na Luo, Ying Duan, Shihao Zhang, Yan Front Psychiatry Psychiatry BACKGROUND AND AIMS: The effect of antidepressant therapy on Inflammatory Bowel Disease (IBD) remains controversial. This trial aimed to assess whether adding venlafaxine to standard therapy for IBD improved the quality of life (QoL), mental health, and disease activity of patients with IBD with anxious and depressive symptoms. METHODS: A prospective, randomized, double-blind, and placebo-controlled clinical trial was conducted. Participants diagnosed with IBD with symptoms of anxiety or depression were randomly assigned to receive either venlafaxine 150 mg daily or equivalent placebo and followed for 6 months. Inflammatory Bowel Disease Questionnaire (IBDQ), Mayo score, Crohn's disease activity index (CDAI), Hospital Anxiety and Depression Scale (HADS), and blood examination were completed before the enrollment, during, and after the follow-up. Mixed linear models and univariate analyses were used to compare groups. RESULTS: Forty-five patients with IBD were included, of whom 25 were randomized to receive venlafaxine. The mean age was 40.00 (SD = 13.12) years old and 25 (55.6%) were male. Venlafaxine showed a significant improvement on QoL (p < 0.001) and disease course (p = 0.035), a greater reduction in HADS (anxiety: p < 0.001, depression: p < 0.001), Mayo scores (p < 0.001), and CDAI (p = 0.006) after 6 months. Venlafaxine had no effect on IL-10 expression, endoscopic scores, relapse rate, and use rate of biologics and corticosteroids, but did reduce serum level of erythrocyte estimation rate (ESR; p = 0.003), C-reactive protein (CRP; p < 0.001) and tumor necrosis factor-α (TNF-α; p = 0.009). CONCLUSIONS: Venlafaxine has a significantly beneficial effect on QoL, IBD activity, and mental health in patients with IBD with comorbid anxious or depressive symptoms. (Chinese Clinical Trial Registry, ID: ChiCTR1900021496). Frontiers Media S.A. 2022-05-19 /pmc/articles/PMC9160994/ /pubmed/35664492 http://dx.doi.org/10.3389/fpsyt.2022.880058 Text en Copyright © 2022 Liang, Chen, Tang, Zhang, Lei, Luo, Duan and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Liang, Chang
Chen, Pingrun
Tang, Yu
Zhang, Chuheng
Lei, Na
Luo, Ying
Duan, Shihao
Zhang, Yan
Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial
title Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial
title_full Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial
title_fullStr Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial
title_full_unstemmed Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial
title_short Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial
title_sort venlafaxine as an adjuvant therapy for inflammatory bowel disease patients with anxious and depressive symptoms: a randomized controlled trial
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160994/
https://www.ncbi.nlm.nih.gov/pubmed/35664492
http://dx.doi.org/10.3389/fpsyt.2022.880058
work_keys_str_mv AT liangchang venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial
AT chenpingrun venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial
AT tangyu venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial
AT zhangchuheng venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial
AT leina venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial
AT luoying venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial
AT duanshihao venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial
AT zhangyan venlafaxineasanadjuvanttherapyforinflammatoryboweldiseasepatientswithanxiousanddepressivesymptomsarandomizedcontrolledtrial